Multiple Sclerosis Clinical Trials
There are 462 actively recruiting multiple sclerosis clinical trials across 64 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Chicago, Illinois, United States, Boston, Massachusetts, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.
Multiple Sclerosis Trials at a Glance
462 actively recruiting trials for multiple sclerosis are listed on ClinicalTrialsFinder across 6 cities in 64 countries. The largest study group is Not Applicable with 175 trials, with the heaviest enrollment activity in Chicago, Boston, and New York. Lead sponsors running multiple sclerosis studies include Novartis Pharmaceuticals, Hoffmann-La Roche, and University of Illinois at Chicago.
Browse multiple sclerosis trials by phase
Top cities for multiple sclerosis trials
Treatments under study
Understanding Multiple Sclerosis Clinical Trials
With over 20 FDA-approved disease-modifying therapies (DMTs) — from interferon beta to highly effective B-cell depleting agents like ocrelizumab (Ocrevus) and ofatumumab (Kesimpta) — multiple sclerosis treatment has advanced dramatically through clinical trials over the past three decades. Yet significant unmet needs remain, particularly for progressive forms of MS where treatment options are limited, and for repair of existing nerve damage. Clinical trials today are pursuing the next frontier: remyelination therapies that aim to restore lost neurological function, not just prevent further damage.
Why Consider a Clinical Trial?
Frequently Asked Questions
Common questions about Multiple Sclerosis clinical trials
It depends on the trial. Some trials allow concurrent DMTs, particularly those studying add-on therapies or symptom management. Others require a washout period from your current DMT before starting the investigational treatment. The washout requirements and timing vary based on which medication you are currently taking and the trial protocol.
Yes. There is a growing number of trials focused on primary progressive MS (PPMS) and secondary progressive MS (SPMS). These trials test BTK inhibitors, neuroprotective agents, remyelination therapies, and combination approaches. Progressive MS trials are a high priority for the research community because effective treatments remain limited.
Most MS trials include MRI scans at screening, baseline, and then every 3 to 6 months during the treatment period. Some trials require more frequent scanning in the early months. These scans are covered by the trial sponsor and use advanced protocols that may detect changes not visible on routine clinical MRI.
Remyelination trials test drugs that aim to repair the protective myelin coating around nerves that is damaged in MS. Unlike current DMTs that reduce inflammation, remyelination therapies could potentially restore lost function. These trials typically measure outcomes using specialized MRI, visual evoked potentials, and functional assessments over 6 to 12 months or longer.
Showing 1–20 of 462 trials